Senti Bio Adds $2M NSG Convertible Note Tranche, Faces Nasdaq Delisting Notices
SNTI is trading near its 52-week low of $0.331 (3.4% above the low) on light trading volume (0.2× avg).
Summary
Senti Bio added a $2.0M convertible note tranche from NSG BioInnovation Fund and received two Nasdaq delisting notices for bid price and stockholders' equity deficiencies.
Key Events · Financing and Capital Events · SNTI
-
NSG Joins as $2M Note Buyer
NSG BioInnovation Fund, L.P. will purchase $2.0 million in senior secured convertible notes in a third tranche, satisfying Celadon Partners SPV 35 Limited's remaining funding obligation under the merger agreement.
-
Nasdaq Bid Price Deficiency
Nasdaq notified Senti Bio that its stock closed below $1.00 for 30 consecutive trading days; the company has until February 23, 2027 to regain compliance, with a possible reverse stock split proposed at the 2026 annual meeting.
-
Nasdaq Equity Deficiency
Nasdaq also notified the company of a $3,401,000 stockholders' deficit as of June 30, 2026, below the $2.5 million minimum; Senti Bio must submit a compliance plan by October 11, 2026.
-
Amendment Allows Multi-Tranche Notes
The Securities Purchase Agreement was amended to permit Notes to be issued in more than two tranches with consent of CPIF II-7 Limited, enabling the NSG third tranche.
Analysis · SNTI · Life Sciences
Senti Bio amended its Securities Purchase Agreement to bring in NSG BioInnovation Fund as a new buyer of $2.0 million in senior secured convertible notes, a third tranche that satisfies Celadon's remaining funding obligation under the merger agreement. The company also received two Nasdaq delisting notices — one for the stock trading below $1.00 for 30 consecutive days and another for a $3.4 million stockholders' deficit versus the $2.5 million minimum. The stock trades at $0.34, near its 52-week low, and the company has until February 23, 2027 to regain bid-price compliance and until October 11, 2026 to submit an equity-compliance plan. The new funding extends the runway but the listing risk is now explicit.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $0.33 to $2.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.